DNA Replication

Definition

• DNA replication: the semiconservative duplication of the genome during S phase, in which each parental strand templates a new complementary strand so that two daughter cells inherit identical, full-length chromosomes.
• Why the details are testable: replication is a chain of separately mutable steps — origin licensing, unwinding, priming, processive synthesis, primer removal, ligation, proofreading, and telomere maintenance. Nearly every inherited syndrome and cytotoxic drug on Step 1 maps to one discrete step, so questions are usually asking "which enzyme?" rather than "what is replication?"

Why it matters clinically

• Fidelity is the link to oncogenesis: polymerase proofreading plus post-replicative mismatch repair keep the somatic mutation rate extremely low. Germline loss of either produces hypermutated tumors — the basis for NCCN-recommended universal mismatch-repair immunohistochemistry or MSI testing on all colorectal and endometrial cancers.
• Proliferating tissues are the drug target: agents that deplete dNTPs, poison topoisomerases, or terminate chains act on the fastest-cycling compartments, which is why myelosuppression, mucositis, and alopecia are the shared toxicity signature of replication-directed chemotherapy.
• Replication stress causes marrow failure: fork-stability and telomere disorders present as aplastic anemia or pulmonary fibrosis long before malignancy appears.

Epidemiology worth recalling

• Lynch syndrome is the most common hereditary colorectal cancer syndrome, accounting for roughly a few percent of colorectal cancers; autosomal dominant, with right-sided colon and endometrial cancer at younger-than-average ages. Average-risk screening begins at age 45 per USPSTF, but NCCN advises substantially earlier and more frequent colonoscopy in confirmed Lynch carriers.
• Bloom syndrome is autosomal recessive and enriched among Ashkenazi Jewish individuals through a founder mutation; Werner, Meier-Gorlin, and LIG4 syndrome are all rare autosomal recessive conditions.
• Fanconi anemia is the most common inherited bone marrow failure syndrome, typically declaring itself in childhood.
• Dyskeratosis congenita most classically presents in males via the X-linked DKC1 form, though autosomal telomere-gene variants exist.

Licensing and initiation (the regulated step)

• Origin licensing: the origin recognition complex (ORC) binds origins in G1; Cdc6 and Cdt1 load the MCM2-7 hexamer, the eukaryotic replicative helicase, forming the pre-replication complex.
• Firing: CDK and DDK (Cdc7) phosphorylation activates MCM2-7 only after the G1/S restriction point, so origin firing — not polymerase speed — is the rate-limiting, tightly regulated event. Licensing occurs once per cell cycle; geminin and CDK-dependent degradation of Cdt1 block re-replication (a key anti-aneuploidy safeguard).

Elongation

• Unwinding and topology: helicase creates the fork; RPA (the eukaryotic single-strand binding protein) coats exposed template; topoisomerase I nicks one strand and topoisomerase II passes duplexes to relieve positive supercoils ahead of the fork.
• Priming: DNA polymerase α/primase lays an RNA–short DNA primer; only after a free 3'-OH exists can a processive polymerase act. Synthesis is obligate 5'→3', driven by pyrophosphate release from the incoming dNTP.
• Processive synthesis: Pol ε handles the leading strand, Pol δ the lagging strand, both clamped by PCNA (loaded by RFC) — the sliding clamp is what converts a distributive enzyme into a processive one.
• Substrate supply: ribonucleotide reductase is rate-limiting for the dNTP pool and is itself S-phase regulated; imbalanced pools raise misincorporation rates.
• Maturation: RNase H and FEN1 remove the flap containing RNA primer, Pol δ fills the gap, and DNA ligase I seals Okazaki fragments (prokaryotes use Pol I's 5'→3' exonuclease and ligase; DnaA/DnaB/gyrase are the bacterial counterparts).

Fidelity and endings

• Proofreading: intrinsic 3'→5' exonuclease excises mismatched 3' termini; mismatch repair (MSH2/MSH6, MLH1/PMS2) is the post-replicative backup, using the nick/PCNA mark to identify the daughter strand.
• End-replication problem: lagging-strand priming cannot copy the extreme 3' template end, so telomeres shorten each division unless telomerase, an RNA-dependent DNA polymerase, extends them.
• Checkpoints: ATR-CHK1 senses stalled forks and RPA-coated ssDNA, halting firing until stress resolves.

Fidelity defects → hypermutation and cancer

• POLE/POLD1 exonuclease-domain mutations: loss of proofreading gives ultramutated colorectal and endometrial tumors with oligopolyposis (polymerase proofreading-associated polyposis), an autosomal dominant syndrome for which NCCN recommends early colonoscopic surveillance and germline testing when tumor mutational burden is extreme without MMR loss.
• Lynch syndrome (MMR: MLH1, MSH2, MSH6, PMS2): replication slippage at repeats produces microsatellite instability; right-sided colon cancer, endometrial cancer, sebaceous neoplasms. NCCN recommends universal MMR immunohistochemistry or MSI testing on colorectal and endometrial tumors, and MSI-high/dMMR status predicts response to PD-1 blockade (FDA tissue-agnostic approval of pembrolizumab).

Helicase and fork-stability defects

• Bloom syndrome (BLM helicase): sister chromatid exchanges, sun-sensitive telangiectatic rash, short stature, immunodeficiency, early leukemia/lymphoma.
• Werner syndrome (WRN): premature aging with cataracts, atherosclerosis, sarcoma.
• Fanconi anemia: interstrand crosslink repair fails at stalled forks → aplastic anemia, café-au-lait macules, radial ray/thumb anomalies, MDS/AML; hypersensitivity to mitomycin C/diepoxybutane is diagnostic.

Initiation-machinery and ligation defects

• Meier-Gorlin syndrome: mutations in pre-replication complex genes (ORC1, ORC4, CDT1, CDC6) → microtia, absent patellae, severe growth restriction — the classic "licensing disease."
• LIG4 syndrome / DNA ligase defects: microcephaly, radiosensitivity, combined immunodeficiency from failed end-joining and ligation.

Telomere maintenance

• Dyskeratosis congenita (DKC1, TERT, TERC): nail dystrophy, oral leukoplakia, reticulated hyperpigmentation, bone marrow failure, pulmonary fibrosis — the short-telomere spectrum.

Pharmacologic exploitation

• Ribonucleotide reductase inhibition: hydroxyurea, used in sickle cell disease (NHLBI sickle cell guidance) and myeloproliferative disease.
• Topoisomerase inhibitors: etoposide (topo II) causes therapy-related AML with 11q23/KMT2A rearrangements; fluoroquinolones inhibit bacterial gyrase/topoisomerase IV and carry FDA boxed warnings for tendinopathy, neuropathy, and aortic events.
• Chain-terminating nucleoside analogs: cytarabine, and NRTIs in HIV therapy (DHHS antiretroviral guidelines), with mitochondrial polymerase γ toxicity as the off-target effect.

• Direction is non-negotiable: synthesis is always 5'→3'; the 3'→5' exonuclease is proofreading, and a separate 5'→3' exonuclease (prokaryotic Pol I; eukaryotic FEN1/RNase H) removes the RNA primer. A stem describing "loss of the 3'→5' exonuclease domain" is testing proofreading, not directionality.
• Sliding clamp = processivity: PCNA (eukaryotes) / β-clamp (prokaryotes) tethers the polymerase; loss reduces processivity, not fidelity.
• Rate-limiting steps examiners like: origin firing requires CDK activity past the restriction point, and ribonucleotide reductase limits dNTP supply — the target of hydroxyurea.
• Universal tumor testing is the single best next step: right-sided colon cancer in a young patient with a family history of endometrial cancer → MMR IHC / MSI testing on the tumor before germline sequencing, per NCCN; dMMR also predicts checkpoint-inhibitor benefit.
• Buzzword pairings: sister chromatid exchanges → Bloom; premature aging with cataracts → Werner; nail dystrophy + oral leukoplakia + marrow failure → dyskeratosis congenita (telomerase); absent patellae + microtia → Meier-Gorlin (origin licensing).
• The classic distractor: xeroderma pigmentosum is defective nucleotide excision repair of UV photoproducts, not a replication-fork enzyme; likewise rifampin inhibits bacterial RNA polymerase, and fluoroquinolones hit gyrase/topoisomerase IV, not DNA polymerase.
• Ends need a specialized enzyme: the end-replication problem exists because the lagging strand cannot be primed at the extreme 3' template terminus; telomerase (reverse transcriptase carrying its own RNA template) solves it, and its reactivation is a near-universal feature of malignancy.
• Every Okazaki fragment needs a fresh primer and a final ligase I seal — ligase failure leaves persistent nicks, so remember ligation as a discrete, separately mutable step (LIG4 syndrome: microcephaly, radiosensitivity, immunodeficiency).

• DNA replication is semi-conservative: each daughter molecule contains one original strand and one newly synthesized strand
• Occurs during S phase of the cell cycle; requires origin of replication and proceeds bidirectionally
• Leading strand synthesized continuously 5'→3'; lagging strand synthesized discontinuously as Okazaki fragments (1000-2000 nt in prokaryotes, 100-200 nt in eukaryotes)
• DNA polymerase III (prokaryotes) or DNA polymerase δ/ε (eukaryotes) catalyzes phosphodiester bond formation; requires RNA primer synthesized by primase
• Error rate ~1 per 10⁹-10¹⁰ bases due to 3'→5' exonuclease proofreading activity

• Board question: "Which strand is synthesized discontinuously?" → Lagging strand
• Question about mutations: Mention a defect in DNA polymerase δ exonuclease activity → increased error rate and cancer risk
• Vignette: "Patient with Xeroderma Pigmentosum" → defective nucleotide excision repair, not replication itself, but comorbid with replication issues

• Confusing DNA polymerase directionality: Synthesis is always 5'→3', not 3'→5' (3'→5' is the exonuclease activity for proofreading)
• Underestimating primase importance: Every Okazaki fragment requires a new primer; primase is essential, not optional
• Mixing up prokaryotic vs. eukaryotic details: Prokaryotes have one replication fork (one origin); eukaryotes have multiple origins; lag fragment sizes differ significantly

• Cancer chemotherapy targets replication: 5-FU (thymidylate synthase inhibitor), gemcitabine (ribonucleotide reductase), methotrexate (folate antagonist)
• Antibiotics targeting bacterial replication: Fluoroquinolones (topoisomerase inhibitors), rifampicin (RNA polymerase, not DNA polymerase)